A breast cancer drug already on the market has been found to lower the chances of breast cancer reoccurring, a medical breakthroughs that increases survival rate.
Daily Intel Newspaper understands that the drug had been approved by the U.S. Food and Drug Administration.
it was further learnt that it is recommended for people with more advanced stages of breast cancer.
Announcing the discovery of the drug in 2023 at an annual meeting of the American Society of Clinical Oncology, founder of the drug, Novartis, said that whereas a vast majority of breast cancers are treated with chemotherapy and endocrine therapy, adding “Kisqali“ after primary treatment will reduce the risk of the cancer coming back.
“The vast majority of breast cancer patients are diagnosed in the early stages of disease. Right now, many are treated with chemotherapy and endocrine therapy.
“The new data shows that adding Kisqali after primary treatment will reduce the risk of the cancer coming back.
“Patients diagnosed with HR+/HER2- early breast cancer remain at risk of cancer recurrence, given that one-third of patients diagnosed with stage II and more than half of those diagnosed with stage III will unfortunately experience a return of their cancer,”
The Pharmaceutical company said results from the clinical trials reinforced the established profile of Kisqali as a proven treatment for HR+/HER2- metastatic breast cancer.
“The compelling data from NATALEE [the clinical trial] highlight the potential of Kisqali to reduce the risk of cancer recurrence in this at-risk population, including node-negative patients, while maintaining a favorable safety profile. These potentially practice-changing results reinforce the unique and well-established profile of Kisqali as a proven treatment in HR+/HER2- metastatic breast cancer.”
